2025年上半年,医药行业一扫过去数年的阴霾,一跃成为资本市场表现最亮眼的板块之一,其中最核心的逻辑,就是中国创新药的崛起。今年上半年,中国创新药出海BD(商务拓展)交易金额超过去年全年,而近期密集披露的半年报数据显示,国产创新药在营收上正迎来快速增长的势头。曾因高研发投入而连续亏损多年的创新药巨头百济神州,今年上半年首度迎来扭亏为盈。公司核心拳头产品泽布替尼(百悦泽)上半年实现全球销售额约125...
Source Link2025年上半年,医药行业一扫过去数年的阴霾,一跃成为资本市场表现最亮眼的板块之一,其中最核心的逻辑,就是中国创新药的崛起。今年上半年,中国创新药出海BD(商务拓展)交易金额超过去年全年,而近期密集披露的半年报数据显示,国产创新药在营收上正迎来快速增长的势头。曾因高研发投入而连续亏损多年的创新药巨头百济神州,今年上半年首度迎来扭亏为盈。公司核心拳头产品泽布替尼(百悦泽)上半年实现全球销售额约125...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.